Drugs / CAR/TRuC-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07508605 | Jan 2025 → Dec 2027 expected | B-cell non-Hodgkin lymphoma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR/TRuC-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07508605 ↗ |
| Modality | Cell therapy | “CD19/CD20 CAR/TRuC-T cell therapy” NCT07508605 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT07508605 ↗ |